1.Hwa, V., Y. Oh, and R. G. Rosenfeld, The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocrine Reviews, 1999. 20(6): p. 761–787.
2.Sprenger, C. C., et al., Over-expression of insulin-like growth factor binding protein-related protein–1 (IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene, 2002. 21(1): p. 140–147.
3.Degeorges, A., et al., Distribution of IGFBP-rP1 in normal human tissues. Journal of Histochemistry & Cytochemistry, 2000. 48(6): p. 747–754.
4.Wajapeyee, N., et al., Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell, 2008. 132(3): p. 363–374.
5.Severino, V., et al., Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells. Cell Death & Disease, 2013. 4.
6.Wilson, H. M. P., et al., Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF–7 breast cancer cells via a senescence-like mechanism. Cell Growth & Differentiation, 2002. 13(5): p. 205–213.
7.Oh, Y. M., et al., Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)–7 - Recombinant human mac25 protein specifically binds IGF-I and II. Journal of Biological Chemistry, 1996. 271(48): p. 30322–30325.
8.Suzuki, H., et al., IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis, 2010. 31(3): p. 342–349.
9.Amemiya, Y., et al., Insulin like growth factor binding protein–7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Research and Treatment, 2011. 126(2): p. 373–384.
10.Chen, Y., et al., Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol, 2007. 211(4): p. 431–8.
11.Vizioli, M. G., et al., IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene, 2010. 29(26): p. 3835–44.
12.Chen, D., et al., Insulin-like Growth Factor-binding Protein–7 (IGFBP7): A Promising Gene Therapeutic for Hepatocellular Carcinoma (HCC). Molecular Therapy, 2013. 21(4): p. 758–766.
13.Kim, J., et al., Epigenetic Downregulation and Growth Inhibition of IGFBP7 in Gastric Cancer. Asian Pac J Cancer Prev, 2018. 19(3): p. 667–675.
14.Liu, L., et al., Decreased expression of IGFBP7 was a poor prognosis predictor for gastric cancer patients. Tumor Biology, 2014. 35(9): p. 8875–8881.
15.Yue, C. Y., et al., IGFBP7 is associated to prognosis and could suppress cell survival in cholangiocarcinoma. Artificial Cells Nanomedicine and Biotechnology, 2018. 46: p. 817–825.
16.Tian, X. Y., et al., Low expression of insulin-like growth factor binding protein 7 associated with poor prognosis in human glioma. Journal of International Medical Research, 2014. 42(3): p. 651–658.
17.An, W., et al., Low Expression of IGFBP7 is Associated with Poor Outcome of Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2012. 19(12): p. 3971–3978.
18.Tomimaru, Y., et al., IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer, 2012. 130(2): p. 319–27.
19.Ruan, W. J., et al., IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biology & Therapy, 2007. 6(3): p. 354–359.
20.Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 2010. 25(9): p. 603–605.
21.Tierney, J. F., et al., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007. 8.
22.Dickersin, K. and J. A. Berlin, Metaanalysis - State-of-the-Science. Epidemiologic Reviews, 1992. 14: p. 154–176.
23.Higgins, J. P. T., et al., Measuring inconsistency in meta-analyses. British Medical Journal, 2003. 327(7414): p. 557–560.
24.Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359–86.
25.Torre, L. A., et al., Global Cancer Statistics, 2012. Ca-a Cancer Journal for Clinicians, 2015. 65(2): p. 87–108.
26.Furstenberger, G. and H. J. Senn, Insulin-like growth factors and cancer. Lancet Oncol, 2002. 3(5): p. 298–302.
27.Mohan, S. and D. J. Baylink, IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. Journal of Endocrinology, 2002. 175(1): p. 19–31.
28.Heesch, S., et al., Expression of IGFBP7 in acute leukemia is regulated by DNA methylation. Cancer Science, 2011. 102(1): p. 253–259.
29.Lin, J., et al., Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression. Journal of Pathology, 2007. 212(1): p. 83–90.
30.Tomimaru, Y., et al., Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. British Journal of Cancer, 2010. 102(10): p. 1483–1490.
31.Okamura, J., et al., Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer. Cancer Biology & Therapy, 2012. 13(3): p. 148–155.
32.Verhagen, H. J. M. P., et al., IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. Cell Death & Disease, 2014. 5.
33.Pen, A., et al., Insulin-like growth factor binding protein 7 exhibits tumor suppressive and vessel stabilization properties in U87MG and T98G glioblastoma cell lines. Cancer Biology & Therapy, 2011. 12(7): p. 634–646.
34.Wajapeyee, N., et al., Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Molecular Cancer Therapeutics, 2009. 8(11): p. 3009–3014.